Invention Grant
- Patent Title: Dihydrobenzimidazolones for medical treatment
-
Application No.: US16809325Application Date: 2020-03-04
-
Publication No.: US11254672B2Publication Date: 2022-02-22
- Inventor: Roger Norcross , Annick Goergler , Fabian Dey , Eric Andre Kusznir
- Applicant: C4 Therapeutics, Inc.
- Applicant Address: US MA Watertown
- Assignee: C4 Therapeutics, Inc.
- Current Assignee: C4 Therapeutics, Inc.
- Current Assignee Address: US MA Watertown
- Agency: Knowles Intellectual Property Strategies, LLC
- Priority: EP17189228 20170904
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D235/26 ; C07D401/14 ; C07D403/10 ; C07D401/10 ; C07D417/10 ; C07D405/12 ; C07D487/08 ; C07D405/14 ; C07D403/14
Abstract:
The present invention provides selected dihydrobenzimidazolones which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and alter the substrate specificity of the CRBN E3 ubiquitin ligase complex, resulting in breakdown of intrinsic downstream proteins. The disclosed compounds are useful for the treatment of cancer.
Public/Granted literature
- US20200207764A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT Public/Granted day:2020-07-02
Information query
